 |
PDBsum entry 1qad
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
292:763-770
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate.
|
|
F.J.Hoedemaeker,
G.Siegal,
S.M.Roe,
P.C.Driscoll,
J.P.Abrahams.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The binding properties of Src homology-2 (SH2) domains to phosphotyrosine
(pY)-containing peptides have been studied in recent years with the elucidation
of a large number of crystal and solution structures. Taken together, these
structures suggest a general mode of binding of pY-containing peptides, explain
the specificities of different SH2 domains, and may be used to design inhibitors
of pY binding by SH2 domain-containing proteins. We now report the crystal
structure to 1.8 A resolution of the C-terminal SH2 domain (C-SH2) of the
P85alpha regulatory subunit of phosphoinositide 3-kinase (PI3 K). Surprisingly,
the carboxylate group of Asp2 from a neighbouring molecule occupies the
phosphotyrosine binding site and interacts with Arg18 (alphaA2) and Arg36
(betaB5), in a similar manner to the phosphotyrosine-protein interactions seen
in structures of other SH2 domains complexed with pY peptides. It is the first
example of a non-phosphate-containing, non-aromatic mimetic of phosphotyrosine
binding to SH2 domains, and this could have implications for the design of
substrate analogues and inhibitors. Overall, the crystal structure closely
resembles the solution structure, but a number of loops which demonstrate
mobility in solution are well defined by the crystal packing. C-SH2 has adopted
a binding conformation reminiscent of the ligand bound N-terminal SH2 domain of
PI3K, apparently induced by the substrate mimicking of a neighbouring molecule
in the crystal.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. Ribbon diagram of the crystal structure of C-SH2.
The various structural elements are labelled using the
nomenclature described by [Eck et al 1993]. The disordered BC
loop (residues 39-42) is indicated with a broken line.
|
 |
Figure 3.
Figure 3. Stereo image of the superposition of the ensemble
of NMR conformers and the crystal structure of C-SH2. The
backbone of the crystal structure is shown in red, while that of
the NMR conformers is shown in blue. The N and C termini are
marked. The disordered BC loop (residues 39-42) is replaced by a
pseudobond between C' of residue 38 and N of residue 43. The
superposition was based on the backbone atoms of residues 11-14,
19-24, 32-37, 43-50, 53-59, 78-86, 103-105.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1999,
292,
763-770)
copyright 1999.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
X.Zhang,
O.Vadas,
O.Perisic,
K.E.Anderson,
J.Clark,
P.T.Hawkins,
L.R.Stephens,
and
R.L.Williams
(2011).
Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.
|
| |
Mol Cell,
41,
567-578.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.B.Gabelli,
D.Mandelker,
O.Schmidt-Kittler,
B.Vogelstein,
and
L.M.Amzel
(2010).
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
|
| |
Biochim Biophys Acta,
1804,
533-540.
|
 |
|
|
|
|
 |
B.S.Jaiswal,
V.Janakiraman,
N.M.Kljavin,
S.Chaudhuri,
H.M.Stern,
W.Wang,
Z.Kan,
H.A.Dbouk,
B.A.Peters,
P.Waring,
T.Dela Vega,
D.M.Kenski,
K.K.Bowman,
M.Lorenzo,
H.Li,
J.Wu,
Z.Modrusan,
J.Stinson,
M.Eby,
P.Yue,
J.S.Kaminker,
F.J.de Sauvage,
J.M.Backer,
and
S.Seshagiri
(2009).
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
|
| |
Cancer Cell,
16,
463-474.
|
 |
|
|
|
|
 |
H.Wu,
S.C.Shekar,
R.J.Flinn,
M.El-Sibai,
B.S.Jaiswal,
K.I.Sen,
V.Janakiraman,
S.Seshagiri,
G.J.Gerfen,
M.E.Girvin,
and
J.M.Backer
(2009).
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
|
| |
Proc Natl Acad Sci U S A,
106,
20258-20263.
|
 |
|
|
|
|
 |
S.Reich,
L.H.Puckey,
C.L.Cheetham,
R.Harris,
A.A.Ali,
U.Bhattacharyya,
K.Maclagan,
K.A.Powell,
C.Prodromou,
L.H.Pearl,
P.C.Driscoll,
and
R.Savva
(2006).
Combinatorial Domain Hunting: An effective approach for the identification of soluble protein domains adaptable to high-throughput applications.
|
| |
Protein Sci,
15,
2356-2365.
|
 |
|
|
|
|
 |
P.J.Scharf,
J.Witney,
R.Daly,
and
B.A.Lyons
(2004).
Solution structure of the human Grb14-SH2 domain and comparison with the structures of the human Grb7-SH2/erbB2 peptide complex and human Grb10-SH2 domain.
|
| |
Protein Sci,
13,
2541-2546.
|
 |
|
|
|
|
 |
F.J.Hoedemaeker,
R.W.Visschers,
A.C.Alting,
K.G.de Kruif,
M.E.Kuil,
and
J.P.Abrahams
(2002).
A novel pH-dependent dimerization motif in beta-lactoglobulin from pig (Sus scrofa).
|
| |
Acta Crystallogr D Biol Crystallogr,
58,
480-486.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Kim,
R.Zagozdzon,
A.Meisler,
J.D.Baleja,
Y.Fu,
S.Avraham,
and
H.Avraham
(2002).
Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer.
|
| |
J Biol Chem,
277,
36465-36470.
|
 |
|
|
|
|
 |
G.Jogl,
X.Tao,
Y.Xu,
and
L.Tong
(2001).
COMO: a program for combined molecular replacement.
|
| |
Acta Crystallogr D Biol Crystallogr,
57,
1127-1134.
|
 |
|
|
|
|
 |
R.A.Pauptit,
C.A.Dennis,
D.J.Derbyshire,
A.L.Breeze,
S.A.Weston,
S.Rowsell,
and
G.N.Murshudov
(2001).
NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex.
|
| |
Acta Crystallogr D Biol Crystallogr,
57,
1397-1404.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.W.Chen
(2001).
Solution solution: using NMR models for molecular replacement.
|
| |
Acta Crystallogr D Biol Crystallogr,
57,
1457-1461.
|
 |
|
|
|
|
 |
Y.W.Chen,
E.J.Dodson,
and
G.J.Kleywegt
(2000).
Does NMR mean "not for molecular replacement"? Using NMR-based search models to solve protein crystal structures.
|
| |
Structure,
8,
R213-R220.
|
 |
|
|
|
|
 |
Y.W.Chen,
and
G.M.Clore
(2000).
A systematic case study on using NMR models for molecular replacement: p53 tetramerization domain revisited.
|
| |
Acta Crystallogr D Biol Crystallogr,
56,
1535-1540.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |